ClinicalTrials.gg
Not yet recruitingNCT07613190Updated May 29, 2026

Adjunctive Oral Iron Supplementation in Atopic Dermatitis

An interventional study of Oral iron in Atopic Dermatitis, sponsored by Cairo University. Not yet recruiting. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
12 Years to 16 Years
Sex
All
01

Study summary

The present randomized controlled trial aims to evaluate the effect of adjunctive oral iron supplementation on disease severity and quality of life in adolescents with mild to moderate atopic dermatitis. In addition, the study will explore whether baseline iron status modifies treatment response and whether changes in iron biomarkers correlate with improvements in clinical severity scores.

02

Conditions studied

  • Atopic Dermatitis

Keywords

  • Atopic dermatitis
  • Iron deficiency
  • Iron supplementation
  • EASI
  • CDLQI
  • SCOٌِRAD
  • EQ-5D-Y
  • Adolescents
  • Randomized controlled trial
03

In context

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

This study's planned enrollment of 124 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adolescents aged 12 to 16 years.
  2. Diagnosis of atopic dermatitis according to Hanifin and Rajka or UK Working Party criteria.
  3. Mild to moderate disease defined as EASI score 1.1-7.0 for mild and 7.1-21.0 for moderate disease, according to the severity classification of Leshem et al. (2015).
  4. Stable standard-of-care topical therapy for at least two weeks prior to enrolment.
  5. Willingness to maintain baseline topical therapy throughout the study period.
  6. Written from a parent or legal guardian and assent from the participant will be obtained prior to enrolment.

Exclusion criteria

Exclusion Criteria:

  • Iron-related exclusions

    1. Known iron overload disorders (e.g., hereditary hemochromatosis).
    2. Ferritin above age- and sex-specific upper reference limits for adolescents (based on local laboratory pediatric reference ranges) in the absence of elevated CRP.
    3. Use of oral or intravenous iron supplementation within the previous three months.

      Hematologic exclusions

    4. less than 8 g/dL. Participants excluded on this basis will be referred to the haematology clinic for evaluation and management of severe anaemia, in accordance with the Declaration of Helsinki (Article 37).
    5. Known hemoglobinopathies (e.g., thalassemia major, sickle cell disease).
    6. Active bleeding or known bleeding disorders. Dermatologic exclusions
    7. Presence of other chronic inflammatory skin diseases that may interfere with assessment (e.g., psoriasis, bullous disorders).
    8. Active skin infection requiring systemic antibiotic therapy.
    9. Use of systemic treatments for atopic dermatitis, including:

      • Systemic
      • Biologic therapies within the following : dupilumab ≥12-16 weeks; cyclosporine ≥4 weeks; methotrexate ≥4-6 weeks; systemic corticosteroids ≥2-4 weeks.

      Systemic exclusions

    10. Severe chronic illnesses that may affect study participation or safety, including:

      • Advanced kidney disease
      • Chronic liver disease
    11. Any other medical condition that, in the investigator's judgment, may interfere with study participation or outcomes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • No intervention
    standard-of-care topical therapy (emollients and steroids)

    Participants will receive standard-of-care topical therapy (emollients and steroids). Standard topical therapies for atopic dermatitis will be continued and documented.

  • Experimental
    standard-of-care topical therapy (emollients and steroids)+ Oral Iron

    Participants will receive (Ferrodunal capsules providing 100 mg elemental oral iron once daily) in addition to standard-of-care topical therapy (emollients and steroids). The 100 mg fixed dose falls within the recommended paediatric dosing range of 3-6 mg/kg/day for most adolescents weighing ≥20 kg. Iron supplementation will be discontinued if serum ferritin exceeds 300 ng/mL on two consecutive measurements.

    Dietary Supplement: Oral iron

Interventions

  • Dietary supplementIronStudies of IronIron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferrodunal capsules providing 100 mg elemental oral iron once daily

06

What researchers measure

Primary outcomes

  1. • Change in Eczema Area and Severity Index (EASI) score from baseline to week 12.

    Higher scores indicate more severe atopic dermatitis, Minimum score is 0 and maximum is 72.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in SCORing Atopic Dermatitis (SCORAD) score from baseline to weeks 6 and 12.

    Higher scores indicate more severe disease and symptoms. Maximum score is 103 and minimum is zero.

    Time frame: 12 weeks

  2. Change in Children's Dermatology Life Quality Index (CDLQI) from baseline to weeks 6 and 12.

    Higher scores indicate greater impairment in quality of life. Score from 0 to 30.

    Time frame: 12 weeks

  3. Change in Patient-Oriented Eczema Measure (POEM) from baselines to weeks 6 and 12.

    Higher scores indicate worse eczema symptoms. Maximum score is 28 and minimum is 0.

    Time frame: 12 weeks

  4. Change in EuroQol Visual Analogue Scale (EQ-VAS) from baseline to weeks 6 and 12.

    Higher scores indicate better perceived overall health. Score is from 0 to 100.

    Time frame: 12 weeks

  5. Change in Peak Pruritus Numerical Rating Scale (PP-NRS) from baseline to weeks 6 and 12.

    Higher scores indicate more severe itching. Score is from 0 to 10.

    Time frame: 12 weeks

  6. Change in serum ferritin from baseline to weeks 6 and 12.

    Time frame: 12 weeks

  7. Proportion of participants achieving EASI-50, EASI-75, and EASI-90.

    Time frame: 12 weeks

  8. Adverse events frequency

    Time frame: 12 weeks

  9. Medication adherence will be assessed through capsule counts at each follow-up visit.

    Time frame: 12 weeks

  10. Correlation between baseline iron status strata and EASI score. (exploratory outcome)

    Time frame: 12 weeks

  11. Correlation between change in iron biomarkers and change in EASI score. (exploratory outcome)

    Time frame: 12 weeks

  12. Change in EQ-5D-Y index score from baseline to weeks 6 and 12.

    Higher scores indicate better health-related quality of life. Usually ≤1 (can be negative in some tariffs).

    Time frame: 12 weeks

  13. Change in serum iron from baseline to weeks 6 and 12.

    Time frame: 12 weeks

  14. Change in serum hemoglobin from baseline to weeks 6 and 12.

    Time frame: 12 weeks

  15. Change in serum CRP from baseline to weeks 6 and 12.

    Time frame: 12 weeks

  16. Medication adherence will be assessed through participant self-report at each follow-up visit.

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2027, 13 months later.

Of 114 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 13 months is below that.

Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2026
First posted
May 29, 2026
StartEst.
May 2026
Primary completionEst.
Jun 2027
CompletionEst.
Oct 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07613190
Lead sponsor
Cairo University
Responsible party
Eglal Adel Mostafa Bassiouny (Dr., Cairo University) — Principal investigator
First posted
May 29, 2026
Start date
May 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
May 29, 2026

Study contacts

Eglal AM Bassiouny, PhD
Contact
eglal.mostafa@pharma.cu.edu.eg
00201061500242
Eglal AM Bassiouny, PhD
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron

Start the discussion